YEAR-END REPORT 2013

The full year 2013 and the fourth quarter in brief

· Net sales increased to MSEK 47.0 (33.2), whereof the fourth quarter MSEK 9.7 (8.6)
· Net loss for the group was reduced to MSEK 22.1 (98.3), whereof the fourth quarter MSEK 3.3 (9.0)
· Loss per share was SEK 0.04 (0.25), whereof the fourth quarter SEK 0.01 (0.02)
· Cash flow from operating activities was MSEK -33.4 (-127.8), whereof the fourth quarter MSEK -7.9 (-20.1)
· Cash and cash equivalents and other short-term investments totaled
MSEK 22.8 (54.1) at the end of the period

Significant events after the end of the reporting period

· The Board of Directors proposes a rights issue with approx 70 MSEK in net proceeds. The share issue is guaranteed to 85 per cent.
· The Board of Directors also proposes a share issue to Anders Lönner of a maximum 15 million share, corresponding to approx. 7 MSEK.
· Anders Lönner will be nominated new Chairman of Karo Bio at the AGM. Göran Wessman will be nominated Director.
· In January 2014, Karo Bio reached a first milestone in the MS project’s collaboration with MS Society, resulting in approximately half of the granted 0.5 MUSD was paid out.

Conference call / audiocast today at 9.30 a.m. CET

CEO Per Bengtsson will present the report today at 9.30 a.m. in an audiocast, held in Swedish. The audiocast and slides are available through the corporate website https://www.karobio.se/ or by telephone +46 8 505 564 87. Questions may be submitted over the internet or by telephone.

For further information, please contact
Per Bengtsson, CEO
Telephone: +46 8 608 6020
E-mail: per.bengtsson@karobio.se
Henrik Palm, CFO
Telephone: +46 8 608 6076 or +46 70 540 4014
E-mail: henrik.palm@karobio.se

Karo Bio AB (publ) Novum 141 57 Huddinge Sweden Telephone: +46 8 608 6000 Corp.reg.nr. 556309-3359 Website: www.karobio.com
The information in this report is such that Karo Bio is required to disclose under the Swedish Securities Market Act. The information was disclosed on February 13, 2014 at 8.30 a.m. CET.